Trial Profile
A multicenter, open, single sequence crossover study to assess the safety and efficacy of a tacrolimus modified release, FK506E (MR4), based immunosuppressive regimen in stable liver transplant patients converted from a Prograf [tacrolimus] based immunosuppressive regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Liver transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 28 Jun 2012 Planned number of patients changed from 106 to 125 as reported by European Clinical Trials Database.
- 18 Feb 2009 Actual patient numbers (112) added as reported by ClinicalTrials.gov.
- 07 May 2008 New trial record.